AR034142A1 - Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion - Google Patents

Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion

Info

Publication number
AR034142A1
AR034142A1 ARP010103968A ARP010103968A AR034142A1 AR 034142 A1 AR034142 A1 AR 034142A1 AR P010103968 A ARP010103968 A AR P010103968A AR P010103968 A ARP010103968 A AR P010103968A AR 034142 A1 AR034142 A1 AR 034142A1
Authority
AR
Argentina
Prior art keywords
composition
manufacturing
pharmaceutical composition
pharmaceutical
medicinal
Prior art date
Application number
ARP010103968A
Other languages
English (en)
Inventor
Maura N Dickler
Clifford A Hudis
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of AR034142A1 publication Critical patent/AR034142A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composición farmacéutica, método para fabricar un medicamento en base a dicha composición y uso de la composición, en donde la composición comprende alrededor de entre 5 y 350 mg de raloxifeno y desde alrededor de entre 5 a 600 mg de exemestano, siendo dicha composición y medicamento para el tratamiento, prevención e inhibición del cáncer de mama.
ARP010103968A 2000-09-08 2001-08-21 Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion AR034142A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65767000A 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
AR034142A1 true AR034142A1 (es) 2004-02-04

Family

ID=24638159

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103968A AR034142A1 (es) 2000-09-08 2001-08-21 Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion

Country Status (7)

Country Link
US (1) US20040009962A1 (es)
EP (1) EP1315483A2 (es)
JP (1) JP2004508325A (es)
AR (1) AR034142A1 (es)
AU (1) AU2001287028A1 (es)
PE (1) PE20020466A1 (es)
WO (1) WO2002020000A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
WO2004010928A2 (en) * 2002-07-25 2004-02-05 Massachusetts Institute Of Technology Steroid modulators in the treatment of peripheral nerve sheath tumors
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
WO2016153819A1 (en) 2015-03-25 2016-09-29 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis using secondary ion mass spectrometry

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356929A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia

Also Published As

Publication number Publication date
AU2001287028A1 (en) 2002-03-22
JP2004508325A (ja) 2004-03-18
PE20020466A1 (es) 2002-06-06
WO2002020000A2 (en) 2002-03-14
WO2002020000A3 (en) 2003-02-27
US20040009962A1 (en) 2004-01-15
EP1315483A2 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
PT1212312E (pt) Novos derivados de flavonas xantonas e cumarinas
ATE292453T1 (de) Antivirale arznei
GB2368525A (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
CR6834A (es) Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo
PT1150704E (pt) Melagatran para o tratamento da inflamacao
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
PL368686A1 (en) Novel aminobenzoephenones
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
CO5210863A1 (es) Medicamento para el tratamiento de urgencia urinaria incre- mentada o incontinencia urinaria . . . . .
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal